DelveInsight’s, “CD3 Antigen Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in CD3 Antigen Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
CD3 Antigen Inhibitors: Overview
Cluster of differentiation 3 (CD3) is a multimeric protein complex, known historically as the T3 complex, and is composed of four distinct polypeptide chains; epsilon (ε), gamma (γ), delta (δ) and zeta (ζ), that assemble and function as three pairs of dimers (εγ, εδ, ζζ). The CD3 complex serves as a T cell co-receptor that associates noncovalently with the T cell receptor
Function - In immunology, Cluster of differentiation 3 as T-cell co-receptor helps to activate the cytotoxic T-Cell. CD3 consists of a protein complex and is composed of four distinct chains. These chains associate with a molecule known as the T-cell receptor (TCR) and the ζ-chain (zeta-chain) to generate an activation signal in T lymphocytes. The TCR, ζ-chain, and CD3 molecules together constitute the TCR complex. The complex functions to transduce intracellular signals during TCR antigen recognition. CD3 epsilon is one of at least three invariant proteins that associate with the variable antigen recognition chains of the T cell receptor and function in signal transduction.
CD3 Antigen Inhibitors - The CD3 protein complex is an important T cell marker for the classification of malignant lymphomas and leukemias (T cell neoplasms). CD3 can also be used for the identification of T cells in coeliac disease, lymphocytic colitis and collagenous colitis. Animal studies have shown that anti-CD3 antibodies induce tolerance to allografts (Nicolls et al. 1993). OKT3, an anti-CD& antibody directed against CD3 ε, has been clinically approved for use in humans for the induction of immunosuppression in solid organ transplantation for the prevention and treatment of rejection. Interestingly, susceptibility to type I diabetes has been associated with the CD3 ε genetic locus and anti-CD3 antibodies have been shown to ameliorate the symptoms of this and other auto-immune disorders. New anticancer drug treatments are being developed based upon the CD3 (cluster of differentiation 3) T cell co-receptor, with molecules being designed for altering the co-stimulatory signal to help get the T-cell to recognize the cancer cell and become fully activated.
The companies and academics are working to assess challenges and seek opportunities that could influence CD3 Antigen Inhibitors R&D. The therapies under development are focused on novel approaches for CD3 Antigen Inhibitors.
This segment of the CD3 Antigen Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CD3 Antigen Inhibitors Emerging Drugs
Tebentafusp: Immunocore
Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the FDA in the United States and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. The drug is currently in phase 3 stage of development.
Cibisatamab: Roche
Cibisatamab is an intravenously administered T-cell bispecific monoclonal antibody, being developed by Roche for the treatment of Non-small cell lung cancer. Currently, it is in phase I/II stage of development.
Further product details are provided in the report……..
This segment of the report provides insights about the different CD3 Antigen Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the CD3 Antigen Inhibitors. The companies which have their CD3 Antigen Inhibitors drug candidates in the most advanced stage, i.e. phase IIIinclude, Immunocore.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
CD3 Antigen Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CD3 Antigen Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD3 Antigen Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
CD3 Antigen Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
CD3 Antigen Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
CD3 Antigen Inhibitors Collaboration Deals
Late Stage Products (Phase III)
Tebentafusp: Immunocore
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Teclistamab: Janssen Research & Development
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Cibisatamab: Roche
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
BNT 142: BioNTech
Drug profiles in the detailed report…..
Inactive Products
CD3 Antigen Inhibitors Key Companies
CD3 Antigen Inhibitors Key Products
CD3 Antigen Inhibitors- Unmet Needs
CD3 Antigen Inhibitors- Market Drivers and Barriers
CD3 Antigen Inhibitors- Future Perspectives and Conclusion
CD3 Antigen Inhibitors Analyst Views
CD3 Antigen Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for CD3 Antigen Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for CD3 Antigen Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Immunocore
• Roche
• Janssen Research & Development
• Celgene Corporation
• Avacta
• MacroGenics
• BioNTech
• Pfizer
• EpimAb Biotherapeutics
• Glenmark Pharmaceuticals
• Tiziana Life Sciences
• IGM Biosciences
• QLSF Biotherapeutics
• Y-mAbs Therapeutics
• Genmab
• YZY Biopharma
• Abzyme Therapeutics
• Harbour BioMed
• Aptevo Therapeutics
• IONTAS
• TeneoBio
• Cullinan Oncology
